3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Penile Neoplasms
1
Non-Small Cell Lung Cancer With HER2- Mutations
1
Melanoma
1
Male Urogenital Diseases
1
Lung Neoplasms
1
First-line Advanced NSCLC Patients
1
Esophageal Squamous Cell Carcinoma
1
Breast Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
3
aldesleukin
2
Paclitaxel
2
Nivolumab
2
Ifosfamide
2
Cisplatin
2
Adoptive Transfer
2
toripalimab
1
pembrolizumab
1
niraparib
1
lenvatinib
1
fludarabine
1
enfortumab vedotin
1
dostarlimab
1
cabozantinib
1
Ultrasonography
1
Specimen Handling
1
Sentinel Lymph Node Biopsy
1
Magnetic Resonance Imaging
1
Ipilimumab
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Cyclophosphamide
1
CTLA-4 Antigen
1
CP protocol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Penile Neoplasms
×
CP protocol
×
Clear all
NCT06353906
2025-12-08
PRIAM
The Netherlands Cancer Institute
Phase 2
Recruiting
27 enrolled